PDUFA date set for idelalisib in lymphoma

Share this article:

Gilead's idelalisib got the all-clear for breakthrough designation for chronic lymphocytic leukemia (CLL), but the FDA is treating the drug like any other therapy when it comes to refractory indolent non-Hodgkin's lymphoma (NHL). BioCentury reports that the FDA set aside September 11 as the PDUFA date for this latter indication.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.